|
Apr 11
|
AstraZeneca’s oral breast cancer drug Truqap greenlit for NHS use
|
|
Apr 10
|
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
|
|
Apr 10
|
Trending tickers: TSMC, Trump Media, US Steel, Novo Nordisk and Tesco
|
|
Apr 9
|
AstraZeneca (LSE:AZN) Gains EU Approval For Breast Cancer Treatment DATROWAY
|
|
Apr 9
|
Why Roche Holding, Eli Lilly, and AstraZeneca Stocks Dropped Today
|
|
Apr 9
|
Trump Says Pharmaceutical Tariffs Coming ‘Very Shortly’
|
|
Apr 9
|
Trending tickers: Apple, Advanced Micro Devices, Ford, BP and AstraZeneca
|
|
Apr 9
|
3 No-Brainer Growth Stocks to Buy for Less Than $100
|
|
Apr 8
|
Astrazeneca (AZN) Stock Moves -1.35%: What You Should Know
|
|
Apr 8
|
AstraZeneca’s camizestrant gains momentum, but questions remain as first-line therapy
|
|
Apr 7
|
AZN Gets EU Nod for Expanded Use of Two Separate Cancer Drugs
|
|
Apr 1
|
AstraZeneca's Imfinzi Gets FDA Nod for Bladder Cancer Indication
|
|
Apr 1
|
AstraZeneca’s AZD0780 cuts LDL-C by 50% in Phase IIb trial
|
|
Apr 1
|
Trending tickers: Tesla, Moderna, Newsmax, Johnson & Johnson and Travis Perkins
|
|
Apr 1
|
FDA approves AstraZeneca’s Imfinzi combo for bladder cancer
|
|
Mar 31
|
Does AstraZeneca Have 'One Pill To Rule Them All' In Cholesterol?
|
|
Mar 31
|
FDA Approves AstraZeneca's Imfinzi As First Perioperative Immunotherapy For Muscle-Invasive Bladder Cancer Patients
|
|
Mar 31
|
AZD0780, a novel oral PCSK9 inhibitor, demonstrated significant LDL cholesterol (LDL-C) reduction in PURSUIT Phase IIb trial
|
|
Mar 31
|
JNJ's Rybrevant-Lazcluze Combo Outshines AZN's Tagrisso in Lung Cancer
|
|
Mar 31
|
IMFINZI® (durvalumab) approved in the US as first and only perioperative immunotherapy for patients with muscle-invasive bladder cancer
|